Abstract:There are two primary concerns in the management of patients with chronic renal failure (CRF) under hemodialysis who are receiving rHEpo for anemia - determine the ideal dose of iron and predict the response to the rHEpo therapy used to treat their anemia. The classic parameters used for monitoring iron therapy in these patients are Transferrin Saturation (TSAT %) and Ferritin (Ferr) concentration. Recently some new red cell parameters have been proposed to support these existing markers as the new research use only (RUO) tests, called Low Hemoglobin Density % (@LHD%®) and Microcytic Anemia Factor (@Maf®), produced by the LH 700 Series hematology analyzers We also have analysed the best hematological parameters to support TSAT % and Ferritin and the best predictors to predict the response to therapy. A total of 30 adult renal dialysis patients receiving EPO for treatment of anemia secondary to end-stage renal disease were enrolled over a six month period from March to August, 2006. The patients were stable with regard to dialysis treatment for at least 3 months prior to entry into the study. Patients had frequent follow up during therapy, consisting of CBC, auto-differential, automated retic %, absolute #, IRF, MRV and RUO parameters. The testing schedule followed the hospital’s existing standard of care with CBC, WBC Differential and Reticulocyte measurements being performed monthly. Iron levels and iron binding capacity were measured before the beginning the study, and then monthly for the duration of the study. These and other chemistry tests were performed on the Beckman Coulter DxC and DxI chemistry and immunoassay instruments and included serum Ferritin, serum iron, TIBC, Transferrin, transferrin saturation, and CRP. A 1 ml aliquot of serum from each sample was frozen for possible additional testing later (soluble transferring receptor (sTfR), etc.). The patients’ anemias were classified using their ferritin and transferrin saturation according to the KDOQI guidelines as Absolute Iron Deficiency (AID), Functional Iron Deficiency (FID) and any iron deficiency: AID or FID (any ID). CRP results were considered in the diagnosis. A response to the rHEpo therapy was defined as an increase in Hemoglobin concentration of 1 g/dL in 2 months, with a minimum increase of 0.3 g/dL per month. The patients’ results were classified as responder or non-responder based on the delta Hgb and delta reticulocyte results from month to month There were 29.3% (41/140) classified as responders. Using a Mann-Whitney test, significant differences (p<0.05) were found for @LHD%, @MAF, MCH comparing patients with TSAT% <20% vs TSAT%>20% and @LHD% for patients with Ferritin <100 ng/mL vs Ferritin> 100 ng/mL) The best RBC parameters for detecting the types of anemias found in these patients were: Detection of IDA was @LHD%® (>4.7%) Detection of FID: MCH (<29.1 g/dL) and @LHD%® (>6.1%) Detection of any ID (AID or FID): @LHD%® (>4.7%) and MCH (<30 g/dL) The best parameter for the prediction of the response to therapy as indicated by an increase in Hgb is @Maf® (<9.2) with a ROC Area under the curve of 0.714. Red Cell parameters can complement the classic parameters used to detect Iron deficiency and predict the response to therapy. The value of these findings to the clinician is that when the classic chemistry parameters are borderline or indeterminate, these new red cell parameters can be use to arrive at a definitive diagnosis and ensure the correct treatment option. @ Research use only parameters

Reference guidelines established in the hospital renal anemia treatment and application of evaluation criteria

Evaluation of the application rationality of erythropoietin and iron treatment for renal anemia

Review of the guidelines and consensus about the treatment of renal anemia

The clinical study to evaluate the hemoglobin target value of anemia treatment in patients with chronic kidney disease

Efficacy,safety and Tolerance of Continuous Erythropoietin Receptor Activator Intravenous Administration on Anemia Correction in Dialysis Patients with Chronic Renal Anemia

Study on Treatment of Anemia and Hemoglobin Variability in Patients with Chronic Kidney Diseases

Research of high and low dose H-rHuEPO on uremic anemia in the maintenance heamodialysis patients

[The Efficacy and Safety of Continuous Erythropoietin Receptor Activator in Dialytic Patients with Chronic Renal Anemia: an Open, Randomized, Controlled, Multi-Center Trial].

Identification Of Different Iron Status And Prediction Of The Response To Therapy With Rhuepo In Patients With Chronic Renal Failure Under Hemodialysis Treatment

Progress of Erythropoietin for Patients with Renal Anemia

Efficacy and Safety of Darbepoetin Alfa Injection Replacing Epoetin Alfa Injection for the Treatment of Renal Anemia in Chinese Hemodialysis Patients: A Randomized, Open‐label, Parallel‐group, Noninferiority Phase III Trial

Systematic review of clinical practice guidelines for kidney disease in China: application of the Appraisal of Guidelines Research and Evaluation-China

The Study of Optimal Dose and Efficacy of Erythropoietin Treatment of Patients with Chemotherapy-Related Anemia

The application of erythrocyte and reticulocyte related indices in anemia and bone marrow transplantation

Cost-effectiveness analysis of oral vs intravenous iron treatment for renal anemia patients

Innovations thérapeutiques dans la prise en charge de l’anémie de la maladie rénale chronique Therapeutic innovations in the management of chronic kidney disease-associated anemia

Concems of Intravenous Iron Therapy in Patients with Renal Anemia

Application of Continous Renal Replacement Therapy in Patients with Critical Hemorrhagic Fever with Renal Syndrome

Evaluation of hepcidin-25/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte/reticulocyte parameters in hemodialysis patients

The Impact of High-Dose Erythropoietin Therapy for Chemotherapy-Relatedanemia

A study of the anemia statues of the chronic kidney disease patient attending the kidney outpatient service